|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||108.62 - 111.09|
|52 Week Range||101.39 - 123.12|
|PE Ratio (TTM)||N/A|
|Expense Ratio (net)||0.48%|
In his first State of the Union speech, President Trump didn’t have any surprises for the markets (SPY). At the annual State of the Union meeting, President Trump addressed a joint session of Congress. President Trump stayed away from any surprise statements that could have spooked the markets.
In 1928, Congress passed a joint resolution establishing Child Health Day, the express purpose of which was to raise awareness “of the fundamental necessity of a year-round program to protect and develop ...
Gilead’s stock price has risen ~8.9% in the last 12 months. Wall Street analysts estimate that the stock price will fall ~4.5% over the next 12 months.
The Cardiovascular and Metabolic Disease (or CVMD segment) contributed ~35.1% of total revenues for AstraZeneca (AZN) in 2Q17.
Bristol-Myers Squibb (BMY) surpassed Wall Street analysts’ estimate for 2Q17 revenues, reporting $5.14 billion compared to the estimate of $5.09 billion.
AstraZeneca (AZN) is one of the largest pharmaceutical companies by revenue. The company operates in over 100 countries and deals with primary care and specialty care medicines.
As discussed earlier, Johnson & Johnson’s (JNJ) 2Q17 performance was positive across all three of its segments. Let’s look at major developments for the company in 2Q17. On July 13,…
Allergan's International segment reported revenues of $737.3 million for 1Q17, which was 9.5% higher than the $673.3 million it reported in 1Q16.
Bristol-Myers reported a net profit of ~$1.57 billion in 1Q17—compared to $1.19 billion in 1Q16. Analysts expect a net profit of $1.18 billion during 2Q16.
Elanco's 1Q17 revenues include revenues from the acquired Novartis Animal Health products. The US Animal Health franchise reported growth of 5% in its 1Q17 revenues to $413.8 million.
The Cardiovascular and Metabolic Disease (or CVMD) segment contributed ~33% of AstraZeneca's (AZN) total revenue in 1Q17.